Overview
iVigee Services provides pharmacovigilance (PV) and regulatory compliance services to pharmaceutical and biotech companies worldwide. It acts as an outsourced PV department across the product lifecycle, handling case intake and processing, signal management, and regulatory intelligence, while also offering strategic consulting to build, assess, and optimize clients’ PV systems for regulatory inspections. The company distinguishes itself through leadership with decades of regulatory and safety experience (including EMA roles) and a patient-safety focus, with an added emphasis on guidance from former regulators and senior safety leaders. It is also integrating Artificial Intelligence to enhance PV workflows, offering AI strategy, implementation, and validation. The overall goal is to help clients stay compliant, protect patients, and run efficient drug-safety operations that meet global regulatory requirements.
Work here?Claim your company
Simplify's take
What believers are saying
- iVigee relaunched its website June 17, 2026, signaling active go-to-market investment.
- October 2026 posts on AI and regulation show fresh thought-leadership velocity.
- A U.S. entity, iVigee USA LLC, expands reach beyond Czech headquarters.
What critics are saying
- Customer concentration risk is severe if one or two biotechs defer PV spend.
- The AI pitch invites inspection scrutiny from EMA and FDA reviewers immediately.
- If AI validation fails, a single adverse finding can destroy trust and referrals.
What makes iVigee Services unique
- Jan Petracek, former EMA risk head, anchors iVigee’s regulatory credibility.
- The September 28, 2026 Agentic AI PV Department bundles services and automation.
- Prague leadership with EU QPPV depth gives clients hands-on inspection readiness.
Help us improve and share your feedback! Did you find this helpful?